Neuroendocrine Tumors: Characterization with Contrast-Enhanced Ultrasonography

被引:52
作者
Doerffel, Y.
Wermke, W. [1 ]
机构
[1] Univ Hosp Charite, Ultrasound Lab, Dept Gastroenterol Hepatol & Endocrinol, Berlin, Germany
来源
ULTRASCHALL IN DER MEDIZIN | 2008年 / 29卷 / 05期
关键词
contrast-enhanced ultrasonography; neuroendocrine tumor; MIB-1;
D O I
10.1055/s-2008-1027555
中图分类号
O42 [声学];
学科分类号
070206 [声学]; 082403 [水声工程];
摘要
Purpose: The aim of this study was to characterize the ultrasonographic features of neuroendocrine tumors (NET) and their metastases with contrast-enhanced ultrasonography (CEUS) and to compare this to clinical data. Materials and Methods: During a period of 5 years, 82 patients with 83 histologically proven NET were prospectively examined using conventional US and Pulse inversion US with a second generation contrast agent (SonoVue (R), Contrast Pulse Sequencing) focusing on the arterial (1020 s p.i.), capillary (20-25 sec p.i.), portal venous (25 - 120 sec p.i.), and late phases (> 120 sec p. i.). 69 patients had metastases in the abdominal tract, including eight patients with poorly differentiated neLlroendocrine carcinomas with high-grade behavior. In 31 patients the proliferation index (MIB-1) of the NET was <= 2%, in 46 patients>2%, in 6 patients >= 20%. Thirteen patients had one primary lesion Without metastases. Results: In NET of the lung, stomach, and colon we found only hypoechoic or isoechoic liver metastases. NET of the small intestine and pancreas represented hypoechoic, isoechoic, and/or hyperechoic liver lesions, sometimes combined. Insulin producing tumors (6) had hypoechoic metastases. Necrotic areas (25/83) were detected after interferon therapy, embolization, systemic chemotherapy, and radiofrequency ablation of liver metastases, but did not develop after somatostatin receptor radionuclide therapy. In large NET (> 3 cm) with a proliferation index of > 2%, necrotic areas appeared spontaneously. In 93% (77/83) of the cases the NET and their metastases showed an early arterial influx of microbubbles. Rim-like contrast enhancement occurred during the capillary phase in 78% (65/83) of all lesions, and hypervascularization Occurred during the arterial phase and at the beginning of the capillary phase in 95% (79/83). The hypervascularized tissue was found in the primary lesions, in liver, lymph node metastases and any kind of abdominal metastases. In liver metastases with a proliferation index >2%, tumor arteries showed a chaotic growth pattern. In 93% (77/83) the NET lesions appeared as dark "defects" at the be.-inning of the late phase. Conclusion: CEUS with CPS demonstrates typical NET imaging characteristics. Differences in imaging features may depend on their primary lesion, size, proliferation marker, and extent of the degenerative changes. In most cases real-time CEUS may replace other imaging techniques.
引用
收藏
页码:506 / 514
页数:9
相关论文
共 25 条
[1]
Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: Multicenter study [J].
Albrecht, T ;
Blomley, MJK ;
Burns, PN ;
Wilson, S ;
Harvey, CJ ;
Leen, E ;
Claudon, M ;
Calliada, F ;
Correas, JM ;
LaFortune, M ;
Campani, R ;
Hoffmann, CW ;
Cosgrove, DO ;
LeFevre, F .
RADIOLOGY, 2003, 227 (02) :361-370
[2]
Guidelines for the use of contrast agents in ultrasound [J].
Albrecht, T ;
Blomley, M ;
Bolondi, L ;
Claudon, M ;
Correas, JM ;
Cosgrove, D ;
Greiner, L ;
Jäger, K ;
de Jong, N ;
Leen, E ;
Lencioni, R ;
Lindsell, D ;
Martegani, A ;
Solbiati, L ;
Thorelius, L ;
Tranquart, F ;
Weskott, HP ;
Whittingham, T .
ULTRASCHALL IN DER MEDIZIN, 2004, 25 (04) :249-256
[3]
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -: The International Lanreotide and Interferon Alfa Study Group [J].
Faiss, S ;
Pape, UF ;
Böhmig, M ;
Dörffel, Y ;
Mansmann, U ;
Golder, W ;
Riecken, EO ;
Wiedenmann, B .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2689-2696
[4]
Hemminki K, 2001, CANCER, V92, P2204, DOI 10.1002/1097-0142(20011015)92:8&lt
[5]
2204::AID-CNCR1564&gt
[6]
3.0.CO
[7]
2-R
[8]
Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment [J].
Jensen, RT .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (04) :368-377
[9]
Tumour biology and histopathology of neuroendocrine tumours [J].
Kloeppel, Guenter .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 21 (01) :15-31
[10]
The gastroenteropancreatic neuroendocrine cell system and its tumors [J].
Klöppel, G ;
Perren, A ;
Heitz, PU .
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 :13-27